Literature DB >> 20935110

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Brett Ley1, Harold R Collard, Talmadge E King.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.

Entities:  

Mesh:

Year:  2010        PMID: 20935110     DOI: 10.1164/rccm.201006-0894CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  485 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

2.  Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.

Authors:  Wen-Qin Zhou; Peng Wang; Qiu-Ping Shao; Jian Wang
Journal:  Mol Cell Biochem       Date:  2016-07-08       Impact factor: 3.396

3.  8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Jonathan Myers; Avraham Unterman; Shimon Izhakian; Jose Oliveira
Journal:  Lung       Date:  2019-01-02       Impact factor: 2.584

Review 4.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 5.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

Review 6.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

7.  Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation.

Authors:  Hayley C Warsinske; Shanna L Ashley; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Bull Math Biol       Date:  2015-09-18       Impact factor: 1.758

8.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

9.  Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis.

Authors:  Tanja Tran; Samy Suissa
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

10.  FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis.

Authors:  Qiang Ding; Guo-Qiang Cai; Meng Hu; Youfeng Yang; Anni Zheng; Qinjiu Tang; Candece L Gladson; Haurko Hayasaka; Hongju Wu; Zhiying You; Brian D Southern; Lisa M Grove; S Ohidar Rahaman; Haotian Fang; Mitchell A Olman
Journal:  Am J Pathol       Date:  2013-03-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.